Cancer deaths in the United States were projected to reach 611,720 in 2024, showing how large the burden remains. Most new cancer cases are diagnosed after symptoms appear, not through screening, with 80% of diagnoses following symptomatic presentation. Across timelines, the median time from an abnormal breast screening result to diagnosis is 23 days, while colorectal diagnosis after an abnormal test takes about 2.0 months.
Key Takeaways
- Cancer deaths in the United States were projected to reach 611,720 in 2024
- 80% of new cancer cases in the United States are diagnosed after the patient shows symptoms (not detected through screening) (SEER-based summary)
- In the U.S., screening prevented an estimated 18% of deaths from colorectal cancer (2015–2019 analysis used in model-based estimates)
- Early detection methods contributed to about 46% of survival gain for colorectal cancer in the U.S. from 1985–2004 (study estimate)
- In the US, the median time from abnormal screening to diagnosis for breast cancer is 23 days (2015–2018 reported in study of diagnostic work-up timelines)
- The median diagnostic interval from first symptomatic presentation to treatment for breast cancer is 46 days (systematic review estimate)
- The median time to diagnosis for colorectal cancer after an abnormal test result is 2.0 months (review estimate)
- The Global Cancer Observatory (GCO) estimates that there were 29.7 million people living with cancer worldwide (2022 estimate)
- The global molecular diagnostics market is projected to reach $93.2 billion by 2028 (forecast)
- The global oncology diagnostics market is expected to reach $39.5 billion by 2030 (forecast)
- The FDA approved first-of-its-kind stool DNA test for colorectal cancer screening (Cologuard) and it targets 2 major stool biomarkers with DNA methylation and hemoglobin detection (test description with regulatory labeling)
- The FDA authorized the first liquid biopsy companion test for NSCLC (Guardant360 CDx) with an intended use for detecting genomic alterations (regulatory summary)
- The FDA approved the first blood-based DNA methylation test for colorectal cancer screening in 2023 (Shielded regulatory record)
- 14.6% of adults (ages 18+) report having been told they have cancer at some point in their lifetime (2019–2020).
- 6.7% of adults (ages 18+) reported no health insurance at the time of interview (U.S., 2022).
With late diagnosis common, faster screening and workup could save lives as global cancer cases rise.
Related reading
01 · Category
Global Burden1 stats
01
Cancer deaths in the United States were projected to reach 611,720 in 2024https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21820
Interpretation
Global Burden Interpretation
The Global Burden picture is stark in the United States, where cancer deaths are projected to rise to 611,720 in 2024, underscoring the continuing and heavy impact of cancer at the population level.
02 · Category
Diagnosis Outcomes4 stats
01
80% of new cancer cases in the United States are diagnosed after the patient shows symptoms (not detected through screening) (SEER-based summary)https://seer.cancer.gov/statfacts/html/all.html
02
In the U.S., screening prevented an estimated 18% of deaths from colorectal cancer (2015–2019 analysis used in model-based estimates)https://www.cdc.gov/mmwr/volumes/70/wr/mm7033a1.htm
03
Early detection methods contributed to about 46% of survival gain for colorectal cancer in the U.S. from 1985–2004 (study estimate)https://jamanetwork.com/journals/jama/fullarticle/203373
04
At least 50% of breast cancer diagnoses in low- and middle-income countries occur at late stage (reviewed estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174784/
Interpretation
Diagnosis Outcomes Interpretation
For diagnosis outcomes, the data show that late detection is a major issue, with 80% of U.S. cancer cases diagnosed only after symptoms appear and at least 50% of breast cancers in low and middle income countries found at a late stage.
03 · Category
Diagnosis Timelines8 stats
01
In the US, the median time from abnormal screening to diagnosis for breast cancer is 23 days (2015–2018 reported in study of diagnostic work-up timelines)https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2794597
02
The median diagnostic interval from first symptomatic presentation to treatment for breast cancer is 46 days (systematic review estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502562/
03
The median time to diagnosis for colorectal cancer after an abnormal test result is 2.0 months (review estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646953/
04
NHS England reported that 70.9% of patients started treatment for cancer within 62 days of referral in 2023 (Cancer Waiting Times dataset)https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/
05
In the U.S., 52% of patients report a delay of 1 month or more from symptom awareness to medical consultation (survey-based estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681474/
06
Median diagnostic delay for lung cancer is reported around 2–3 months in observational studies (review estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248612/
07
In a scoping review, diagnostic delay for cancers ranged from 13 to 210 days across studies (range reported in review)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200462/
08
In the U.S., 7.6% of adults had no usual source of care (affecting diagnostic access)https://www.cdc.gov/nchs/fastats/health-insurance.htm
Interpretation
Diagnosis Timelines Interpretation
Across major cancers in the Diagnosis Timelines category, patients often wait weeks to months between first signals and treatment, with median intervals of 23 days for breast cancer after abnormal screening and 46 days from first symptoms to treatment, while 70.9% in England start cancer treatment within 62 days of referral and other studies show delays of about 2.0 months for colorectal cancer and roughly 2 to 3 months for lung cancer.
04 · Category
Market Size11 stats
01
The Global Cancer Observatory (GCO) estimates that there were 29.7 million people living with cancer worldwide (2022 estimate)https://gco.iarc.fr/today/factsheets/populations/900-world-fact-sheets.pdf
02
The global molecular diagnostics market is projected to reach $93.2 billion by 2028 (forecast)https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostics-market-858.html
03
The global oncology diagnostics market is expected to reach $39.5 billion by 2030 (forecast)https://www.fortunebusinessinsights.com/oncology-diagnostics-market-102536
04
The global liquid biopsy market size was valued at $5.2 billion in 2023https://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market
05
The global digital pathology market is expected to reach $5.6 billion by 2030 (forecast)https://www.fortunebusinessinsights.com/digital-pathology-market-106861
06
The global AI in healthcare market is expected to grow to $187.95 billion by 2030 (forecast)https://www.fortunebusinessinsights.com/artificial-intelligence-in-healthcare-market-102980
07
The global imaging informatics market is projected to reach $13.0 billion by 2030 (forecast)https://www.marketsandmarkets.com/Market-Reports/imaging-informatics-market-1177.html
08
The global radiology information system (RIS) market is projected to reach $1.4 billion by 2030 (forecast)https://www.marketsandmarkets.com/Market-Reports/radiology-information-system-ris-market-1105.html
09
The global next-generation sequencing (NGS) market was estimated at $8.8 billion in 2023https://www.grandviewresearch.com/industry-analysis/next-generation-sequencing-market
10
The global histopathology services market is projected to reach $31.3 billion by 2030 (forecast)https://www.fortunebusinessinsights.com/histopathology-services-market-106258
11
The global pathology automation market is expected to reach $4.4 billion by 2030 (forecast)https://www.fortunebusinessinsights.com/pathology-automation-market-105769
Interpretation
Market Size Interpretation
With 29.7 million people living with cancer globally in 2022 and major diagnostics segments projected to expand rapidly such as molecular diagnostics reaching $93.2 billion by 2028 and AI in healthcare growing to $187.95 billion by 2030, the market size for cancer diagnosis is clearly on a strong upward trajectory.
05 · Category
Industry Trends3 stats
01
The FDA approved first-of-its-kind stool DNA test for colorectal cancer screening (Cologuard) and it targets 2 major stool biomarkers with DNA methylation and hemoglobin detection (test description with regulatory labeling)https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?id=K140217
02
The FDA authorized the first liquid biopsy companion test for NSCLC (Guardant360 CDx) with an intended use for detecting genomic alterations (regulatory summary)https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190006C.pdf
03
The FDA approved the first blood-based DNA methylation test for colorectal cancer screening in 2023 (Shielded regulatory record)https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?id=P230004
Interpretation
Industry Trends Interpretation
From the Industry Trends perspective, the FDA has moved from approving Cologuard that targets 2 stool biomarkers to authorizing a liquid biopsy companion test and then in 2023 adding a blood based DNA methylation screening option, showing a clear push toward more targeted and diversified cancer screening tests.
More related reading
06 · Category
Disease Burden1 stats
01
14.6% of adults (ages 18+) report having been told they have cancer at some point in their lifetime (2019–2020).https://www.cdc.gov/brfss/annual_data/annual_2020.html
Interpretation
Disease Burden Interpretation
Under the disease burden lens, 14.6% of adults aged 18 and older report being told they have cancer at some point in their lifetime, highlighting a substantial lifelong impact on the population.
07 · Category
Cost & Access3 stats
01
6.7% of adults (ages 18+) reported no health insurance at the time of interview (U.S., 2022).https://www.census.gov/library/publications/2023/demo/p60-280.html
02
34% of adults report difficulty accessing transportation for medical care (U.S., 2022).https://www.cdc.gov/nchs/data/nhsr/nhsr173.pdf
03
6.5% of U.S. adults reported not having a routine checkup within the past year (2022).https://www.cdc.gov/nchs/data/nhis/earlyrelease/insur202312.pdf
Interpretation
Cost & Access Interpretation
In the U.S., cost and access barriers remain significant for cancer-related care, with 6.7% of adults lacking health insurance and 34% reporting difficulty getting transportation for medical care, while 6.5% did not get a routine checkup in the past year.
08 · Category
Diagnosis Pathways2 stats
01
1.6 million Americans were newly diagnosed with cancer in 2019 (global estimate used by National Cancer Institute).https://www.cancer.gov/about-cancer/understanding/statistics
02
Diagnostic imaging utilization is projected to grow at a 3.2% CAGR through 2030 in the U.S. (imaging procedures demand forecast).https://www.diagnosticimaging.com/view/u-s-imaging-procedures-to-grow-through-2030
Interpretation
Diagnosis Pathways Interpretation
With 1.6 million Americans newly diagnosed with cancer in 2019 and U.S. diagnostic imaging expected to grow 3.2% annually through 2030, diagnosis pathways are likely to become increasingly imaging driven to meet rising demand.
09 · Category
Technology & Testing6 stats
01
$8.8 billion global NGS market size in 2023 (includes research and oncology diagnostics).https://www.genomeweb.com/business-market-trends/next-generation-sequencing-market-reached-8-8b-2023-report
02
$5.2 billion global liquid biopsy market value in 2023 (diagnostic tests and related services).https://www.globenewswire.com/news-release/2024/02/05/2824796/0/en/Liquid-Biopsy-Market-Size-Share-Trends-Analysis-Report-by-Test-Method-By-End-User-Forecast-2024-2034.html
03
$5.6 billion global digital pathology market expected by 2030 (software and services).https://www.marketscreener.com/quote/stock/VENTURE-CRAFT-TECHNOLOG-40930130/news/Digital-Pathology-Market-Size-to-Reach-US-5-6-Bn-by-2030-Report-by-VMR-2023-Share-Trends-43753672/
04
$93.2 billion global molecular diagnostics market projected by 2028 (forecast).https://www.statista.com/statistics/1297140/molecular-diagnostics-market-size-forecast/
05
$187.95 billion global AI in healthcare market expected by 2030 (forecast).https://www.statista.com/statistics/1165950/artificial-intelligence-in-healthcare-market-size-forecast/
06
$39.5 billion global oncology diagnostics market expected by 2030 (forecast).https://www.statista.com/statistics/1258799/oncology-diagnostics-market-size-forecast/
Interpretation
Technology & Testing Interpretation
The Technology and Testing landscape for cancer is expanding fast, with the global molecular diagnostics market projected to reach $93.2 billion by 2028 and digital pathology growing to $5.6 billion by 2030 as AI in healthcare climbs toward $187.95 billion by 2030.
report visual · Key figures
Cancer diagnosis and access delays
A large share of cancer patients experience diagnostic delays, and many cases are diagnosed after symptoms rather than through screening.
80%
80% of new cancer cases in the United States are diagnosed after the patient shows symptoms (not detected through screen
70.9%
NHS England reported that 70.9% of patients started treatment for cancer within 62 days of referral in 2023 (Cancer Wait
52%
In the U.S., 52% of patients report a delay of 1 month or more from symptom awareness to medical consultation (survey-ba
2.0
The median time to diagnosis for colorectal cancer after an abnormal test result is 2.0 months (review estimate)
2
Median diagnostic delay for lung cancer is reported around 2–3 months in observational studies (review estimate)
46
The median diagnostic interval from first symptomatic presentation to treatment for breast cancer is 46 days (systematic
source-verifiedseer.cancer.gov · england.nhs.uk · ncbi.nlm.nih.gov2023
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Thomas Lindqvist. (2026, February 13). Cancer Diagnosis Statistics. Gitnux. https://gitnux.org/cancer-diagnosis-statistics
MLA
Thomas Lindqvist. "Cancer Diagnosis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cancer-diagnosis-statistics.
Chicago
Thomas Lindqvist. 2026. "Cancer Diagnosis Statistics." Gitnux. https://gitnux.org/cancer-diagnosis-statistics.
Sources & references
39 datasets cited across this report
+21 additional datasets cited (not shown individually)